AI for NDSRIs with positive EAT and/or in-vivo mutagenicity study - FDA position?
|
|
2
|
469
|
November 9, 2023
|
Vilazodone Nitrosamine
|
|
0
|
324
|
October 31, 2023
|
Review of nitrosamine drug substance related impurities (ndsri) in pharmaceutical drugs
|
|
1
|
594
|
October 31, 2023
|
Personal perspective on N-Nitrosamines and recent revision of guidelines
|
|
7
|
654
|
October 27, 2023
|
Reflections on the Impact of Nitrosamine Drug Substance Related Impurities
|
|
0
|
342
|
October 20, 2023
|
CPCA is now included in the updated version of Health Canada’s Guidance on nitrosamine impurities
|
|
15
|
2126
|
October 13, 2023
|
NDSRIs: Analytical Challenges/ Desafios Analíticos
|
|
0
|
477
|
October 11, 2023
|
Variation requirements
|
|
2
|
385
|
October 2, 2023
|
关于2023药物杂质控制国际交流会的资讯
|
|
1
|
384
|
September 29, 2023
|
🇺🇸 FDA - Recommended Acceptable Intake Limits for NDSRIs Guidance for Industry
|
|
47
|
5783
|
September 20, 2023
|
Nitrosamine in DS and DP specifications
|
|
2
|
704
|
September 20, 2023
|
Apixaban Drug Substance-Related Impurities (NDSRIs)
|
|
3
|
1034
|
September 15, 2023
|
🇪🇺 EMA Q&A Rev. 16 EMA/409815/2020 - MAJOR UPDATE
|
|
108
|
17302
|
September 12, 2023
|
DP Method transfer and verification
|
|
8
|
569
|
August 31, 2023
|
Optimized method development strategies for the quantification of small and complex N-nitrosamines impurities
|
|
0
|
415
|
August 25, 2023
|
Approaches and Considerations for the Investigation and Synthesis of N‑Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
0
|
543
|
August 23, 2023
|
Nitrosaminas: Estrutura química vs Potencial carcinogênico
|
|
3
|
475
|
August 23, 2023
|
N-Nitroso N-Desmethyl Nefopam
|
|
4
|
691
|
August 18, 2023
|
Total impurities limit if more than one nitrosamine impurities are observed in product
|
|
4
|
537
|
August 14, 2023
|
Planilha CPCA na prática
|
|
0
|
318
|
August 6, 2023
|
FDA Workshop: Mitigation Strategies for Nitrosamine Drug Substance Related Impurities
|
|
11
|
2804
|
July 27, 2023
|
Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies
|
|
3
|
803
|
July 26, 2023
|
Case Studies for CPCA Scoring
|
|
12
|
3031
|
July 25, 2023
|
NDSRIs: Atualizações e Desafios
|
|
0
|
390
|
July 24, 2023
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
1270
|
July 20, 2023
|
😞 Aripiprazole is not approvable since 'major objections' have been identified
|
|
6
|
664
|
July 18, 2023
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
2
|
1261
|
July 3, 2023
|
The 18 ng/day default for NDSRIs should be re-visited?
|
|
8
|
831
|
June 14, 2023
|
FDA solicit comments on assessment of NDSRIs
|
|
12
|
1826
|
July 11, 2023
|
Formation of N-nitroso Fluconazole and Related Triazole-Imidazole APIs
|
|
4
|
878
|
June 9, 2023
|